Ations in to the sedating (olanzapine and quetiapine) and non-sedating (risperidone, aripiprazole, and ziprasidone) subgroups.

Ations in to the sedating (olanzapine and quetiapine) and non-sedating (risperidone, aripiprazole, and ziprasidone) subgroups. Lastly, the evaluation also examined HRQoL amongst patients who had completed or discontinued treatment with lurasidone because of any cause at study endpoint.ResultsPatient demographics baseline characteristicsThe study population was comprised of 240 individuals with schizophrenia or schizoaffective disorder who received no less than a single dose of study medication. Table 1 presents the baseline clinical traits for the total study population. Of the 240 patients switched to lurasidone from other antipsychotics, 235 individuals with available data on the PETiT scale and SF-12 assessment comprised the ITTAwad et al. BMC Psychiatry 2014, 14:53 http://biomedcentral/1471-244X/14/Page 4 ofTable 1 Patient demographics and baseline clinical characteristicsParameter N Imply age Years, SD Gender Male Female Race Asian Black or African American Native Hawaiian or other Pacific Islander White Other DSM-IV Schizophrenia subtype diagnosis 295.10 Disorganized variety 295.20 Catatonic variety 295.30 Paranoid kind 295.60 Residual sort 295.70 Schizoaffective disorder 295.90 Undifferentiated variety Preswitch antipsychotic agent at study begin Quetiapine Risperidone Aripiprazole Ziprasidone Olanzapine Paliperidone Iloperidone Asenapine First-generation antipsychotic Therapy with concomitant lithium, valproate or lamotrigine Treatment with concomitant antidepressant Imply age (SD) at initial onset of schizophrenia or schizoaffective disorder, years Imply good and adverse syndrome scale total score (SD) Mean clinical global impression severity score (SD)or as indicated.83 of 235 (35 ) had been treated with a preswitch sedating medication (olanzapine or quetiapine).PETiT assessmentNo. of subjects ( )43.9 (ten.9)156 (65.0 ) 84 (35.0 )1 (0.4 ) 151 (62.9 ) 1 (0.4 ) 80 (33.three ) 7 (2.9 )The imply (standard deviation [SD]) PETiT total score for all lurasidone patients improved from 35.0 (8.eight) at baseline to 38.5 (9.2) at LOCF endpoint, representing a imply improvement of three.2 (8.five) or 9.1 (p 0.001). Improvements from baseline to LOCF endpoint inside the total score, too as in the domains of adherence-related attitude (0.7 [2.6]) and psychosocial functioning (2.5 [6.9]), were statistically substantial (p 0.002) for all patients who were switched to lurasidone (Table 2). All elements of the psychosocial functioning domain (activity, cognitive, and dysphoria) showed significant improvement (p 0.002) using the exception of social functioning, where a non-significant improvement was demonstrated.PETiT scores by preswitch antipsychotic medication4 (1.7 ) 0 125 (52.1 ) 2 (0.8 ) 89 (37.1 ) 21 (eight.8 )62 (25.eight ) 51 (21.three ) 44 (18.3 ) 27 (11.3 ) 24 (ten.0 ) 9 (3.8 ) 4 (1.7 ) two (0.8 ) 17 (7.1 ) 34 (16.2 ) 104 (43.3 ) 25.1 (9.3) 68.9 (13.eight) three.7 (0.five)The variations in patients’ PETiT scores have been also stratified according to the antipsychotic medication made use of prior to switching to lurasidone. To make sure a reasonable Kainate Receptor Antagonist supplier sample size for this analysis, preswitch antipsychotic medications received by 10 of individuals inside the study had been ERα Agonist Source incorporated for stratification. The drugs incorporated quetiapine (n = 62), risperidone (n = 51), aripiprazole (n = 44), ziprasidone (n = 27), and olanzapine (n = 24). Patients on all of these preswitch medicines except olanzapine showed statistically important improvements in total PETiT scores, as determined by imply alterations from baseline to LOCF ( D): q.